The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).
 
Andrew X. Zhu
Research Funding - Lilly (Inst)
 
Peter R. Galle
Honoraria - ArQule; Bayer; Bristol-Myers Squibb; Lilly; Transgene
Consulting or Advisory Role - ArQule; Bayer; Bristol-Myers Squibb; Lilly; Transgene
Speakers' Bureau - Bayer
Travel, Accommodations, Expenses - ArQule; Bayer; Bristol-Myers Squibb; Lilly; Transgene
 
Masatoshi Kudo
Honoraria - Ajinomoto; Bayer; Eisai; Kaken Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Chugai Pharma; Kowa; Taiho Pharmaceutical
Research Funding - Bayer; Bristol-Myers Squibb; Chugai Pharma; Kowa; Lilly; Novartis; Pfizer; Taiho Pharmaceutical
 
Richard S. Finn
Consulting or Advisory Role - Pfizer
Research Funding - Pfizer (Inst)
 
Ling Yang
Employment - Lilly
 
Paolo Abada
Employment - Lilly
 
Josep M. Llovet
Consulting or Advisory Role - Bayer; Biocompatibles; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celsion; GlaxoSmithKline; Lilly; Novartis
Research Funding - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bayer